Repligen CEO Loeillot sells $2.46m in shares

On September 24, 2026, Repligen Corp.'s CEO, Olivier Loeillot, sold approximately $2.46 million worth of the company's common stock, totaling 12,946 shares. This sale was executed under a Rule 10b5-1 trading plan, with each share priced at $190.00. The transactions occurred as RGEN shares were near their 52-week high of $192.49, following a 51% return over the past year.

However, the stock was deemed overvalued by InvestingPro, trading at a P/E ratio of 260. Simultaneously, Loeillot acquired 12,946 shares through stock options, purchasing 8,404 shares at $154.96 and 4,542 shares at $155.38, amounting to a total value of $2.01 million. After these transactions, he directly holds 48,369 shares of Repligen common stock.

The Form 4 filing detailing the ownership changes was signed by Jennifer Carmichael as Attorney in Fact on September 25, 2026. Recently, Repligen reported its second-quarter 2026 earnings, surpassing analyst expectations with adjusted earnings of $0.54 per share, exceeding the forecasted $0.45 per share. Revenue for the quarter was $204 million, slightly above the anticipated $201.47 million, indicating modest revenue growth.

The company also raised its full-year outlook, signaling a positive trajectory. Canaccord Genuity maintained a Hold rating on Repligen with a price target of $145. These developments highlight Repligen's ability to outperform earnings estimates and provide an optimistic outlook for the remainder of the year.